The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zakiev V.D.

Russian State Social University;
Research Center for Comorbid Diseases «Rational Medicine»

Martynyuk T.V.

Chazov National Medical Research Center for Cardiology;
Pirogov Russian National Research Medical University

Vedernikov A.A.

Sechenov First Moscow State Medical University

Petrenko D.A.

Sechenov First Moscow State Medical University

Korkach-Romanov S.V.

LABMGMU LLC

Socio-economic burden of newly diagnosed pulmonary arterial hypertension and early specific treatment initiation impact on the costs in real clinical practice in Russia

Authors:

Zakiev V.D., Martynyuk T.V., Vedernikov A.A., Petrenko D.A., Korkach-Romanov S.V.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2023;45(1): 99‑113

DOI: 10.17116/medtech20234501199

Views: 1381

Downloaded: 37

Download PDF (RU)
Contact the author
Table of contents

SOCIO-ECONOMIC BURDEN OF NEWLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION AND EARLY SPECIFIC TREATMENT INITIATION IMPACT ON THE COSTS IN REAL CLINICAL PRACTICE IN RUSSIA
SOCIO-ECONOMIC BURDEN OF NEWLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION AND EARLY SPECIFIC TREATMENT INITIATION IMPACT ON THE COSTS IN REAL CLINICAL PRACTICE IN RUSSIA

To cite this article:

Zakiev VD, Martynyuk TV, Vedernikov AA, Petrenko DA, Korkach-Romanov SV. Socio-economic burden of newly diagnosed pulmonary arterial hypertension and early specific treatment initiation impact on the costs in real clinical practice in Russia. Medical Technologies. Assessment and Choice. 2023;45(1):99‑113. (In Russ.)
https://doi.org/10.17116/medtech20234501199

 
 
Подписка 2025-2 (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Close metadata
Recommended articles:
Pulmonary arte­rial hype­rtension in diso­rders of porto-caval hemo­dynamics. The role of ultrasound diagnostics. Russian Cardiology Bulletin. 2025;(1):90-98

OBJECTIVE

To assess the use of health care resources and socioeconomic burden in patients with newly diagnosed pulmonary arterial hypertension before diagnosis and throughout 12-month treatment, as well as the impact of treatment on these indicators in real clinical practice.

MATERIAL AND METHODS

A retrospective-prospective observational study included patients with various forms of pulmonary arterial hypertension. The diagnosis was verified by right heart catheterization. The data were collected by interviewing patients and reviewing medical records at inclusion in the study and every 3 months later. Some patients (57.6%) were included in the study a few months after right heart catheterization, but not more than 12 months later. We analyzed direct and indirect costs. The total follow-up period for each patient was 1 year before diagnosis and 1 year later.

RESULTS

The study included 33 patients. The median of annual expenses per a patient with pulmonary arterial hypertension was 234.570.07 rubles before diagnosis and 1.501.175.08 rubles after diagnosis. The median of direct costs was 110.661/902.456 rubles, direct non-medical costs — 2.213/74.025 rubles, indirect costs — 80.477/52.972 rubles before and after verification of pulmonary arterial hypertension, respectively. Thus, verification of diagnosis was followed by significant increase in costs for pulmonary arterial hypertension due to specific therapy (p=0.11·10–4). At the same time, establishing the diagnosis of pulmonary arterial hypertension significantly decreased all direct costs, except for the cost of specific therapy, and expenses for hospital-stay (p=0.11·10–4). There were no significant differences in direct non-medical (p=0.53) and indirect costs after verification of diagnosis (p=0.31).

CONCLUSION

Early diagnosis and availability of specific therapy will improve the quality of care for patients with pulmonary arterial hypertension and incur reasonable government costs for the treatment of these patients. Despite higher expenses for specific therapy, its early initiation can improve quality of life and avoid additional costs for hospital-stay.

Keywords:

pulmonary hypertension
disease cost
economic burden

Authors:

Zakiev V.D.

Russian State Social University;
Research Center for Comorbid Diseases «Rational Medicine»

Martynyuk T.V.

Chazov National Medical Research Center for Cardiology;
Pirogov Russian National Research Medical University

Vedernikov A.A.

Sechenov First Moscow State Medical University

Petrenko D.A.

Sechenov First Moscow State Medical University

Korkach-Romanov S.V.

LABMGMU LLC

Received:

31.10.2022

Accepted:

29.11.2022

List of references:

  1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal. 2023 Jan 6;61(1):2200879. https://doi.org/10.1183/13993003.00879-2022
  2. Chazova IE, Martynyuk TV, Valieva ZS, Azizov VA, Barbarash OL, Veselova TN, et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Evrazijskij kardiologicheskij zhurnal. 2020;(1):78-122. (In Russ.). https://doi.org/10.38109/2225-1685-2020-1-78-122
  3. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulmonary Circulation. 2021;11(1):2045894020977300. https://doi.org/10.1177/2045894020977300
  4. Örem C. Epidemiology of pulmonary hypertension in the elderly. Journal of Geriatric Cardiology. 2017;14(1):11-16.  https://doi.org/10.11909/j.issn.1671-5411.2017.01.001
  5. Komitet Gosudarstvennoj Dumy po ohrane zdorov’ya. Gosudarstvennaya Duma Federal’nogo Sobraniya Rossijskoj Federacii. Ezhegodnyj byulleten’ Ekspertnogo soveta po redkim (orfannym) zabolevaniyam. M. 2021. Accessed December 1, 2022. (In Russ.). https://www.komitet2-2.km.duma.gov.ru/upload/site21/Byulleten_po_redkim_zabolevaniyam_2021.pdf
  6. Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension In Russia: six-year observation analysis of the National Registry. Terapevticheskiy arkhiv. 2019;91(1):24-31. (In Russ.). PMID: 31090367.
  7. Gosudarstvennyj reestr lekarstvennyh sredstv. Accessed October 11, 2021. (In Russ.). https://grls.rosminzdrav.ru/Default.aspx
  8. Serpik VG, Arinina EE. Pharmacoeconomic analysis of the treatment of pulmonary arterial hypertension in the Russian Federation. Farmakoekonomika: teoriya i praktika. 2016;4(3):40-46. (In Russ.). https://doi.org/10.30809/phe.3.2016.4
  9. Khabriev RU, Yagudina RI, Pravdyuk NG. Ocenka tekhnologij zdravoohraneniya. M.: Medicinskoe informacionnoe agentstvo; 2013. (In Russ.).
  10. Ocenka medicinskih tekhnologij. Mezhdunarodnyj opyt. Pod red. Starodubova VI, Kagramanyana IN. M. 2012. (In Russ.).
  11. Yagudina RI, Zinchuk IYu, Litvinenko MM. Cost of illness analysis: types, methodology, Russian specifics. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2012;5(1):4-9. (In Russ.).
  12. Zelenova OV, Abramov SI, Kreknina EA, Zelenova EG. Social cost of disease — new opportunities for decision making. Through the example of the complications’ therapy cost in type 2 diabetes. Rany i ranevye infekcii. Zhurnal im. prof. B.M. Kostyuchyonka. 2017;4(1):6-13. (In Russ.). https://doi.org/10.17650/2408-9613-2017-4-1-6-13
  13. Drummond ME, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; 1999.
  14. Metodicheskie rekomendacii po raschetu zatrat pri provedenii kliniko-ekonomicheskih issledovanij lekarstvennyh preparatov. M.: FGBU «Centr ekspertizy i kontrolya kachestva medicinskoj pomoshchi» Ministerstva zdravoohraneniya Rossijskoj Federacii; 2017. Accessed October 11, 2021. (In Russ.). https://rosmedex.ru/wp-content/uploads/2018/02/Metodicheskie-rekomendatsii-po-raschetu-zatrat-pri-provedenii-kliniko-e%60ko-nomicheskih-issledovaniy-lekarstvennyih-preparatov-2017.pdf
  15. Chazova IE, Martynyuk TV, Valieva ZS, Nakonechnikov SN, Nedogoda SV, Salasyuk AS, et al. The economic burden of chronic thromboembolic pulmonary hypertension In Russian Federation. Terapevticheskiy arkhiv. 2018;90(9):101-109. (In Russ.). https://doi.org/10.26442/terarkh2018909101-109
  16. Gosudarstvennyj reestr predel’nyh otpusknyh cen proizvoditelej na lekarstvennye preparaty, vklyuchennye v perechen’ zhiznenno neobhodimyh i vazhnejshih lekarstvennyh preparatov. Accessed October 11, 2021. (In Russ.). https://grls.rosminzdrav.ru/pricelims.aspx
  17. Predel’nye razmery optovyh nadbavok i predel’nye razmery roznichnyh nadbavok k cenam na zhiznenno neobhodimye i vazhnejshie lekarstvennye preparaty, ustanovlennye v sub»ektah Rossijskoj Federacii. Sajt Federal’noj antimonopol’noj sluzhby Rossii. Accessed October 11, 2021. (In Russ.). https://fas.gov.ru/documents/687688
  18. Informacionnyj Web-portal «Spravmedika». Accessed October 11, 2021. (In Russ.). https://003ms.ru/
  19. Edinaya informacionnaya sistema v sfere gosudarstvennyh zakupok. Accessed October 11, 2021. (In Russ.). https://zakupki.gov.ru/epz/main/public/home.html
  20. Tarifnoe soglashenie na oplatu medicinskoj pomoshchi, okazyvaemoj po territorial’noj programme obyazatel’nogo medicinskogo strahovaniya goroda Moskvy na 2021 god. Moskovskij gorodskoj fond obyazatel’nogo medicinskogo strahovaniya. Accessed October 11, 2021. (In Russ.). https://www.mgfoms.ru/medicinskie-organizacii/tarifi/2021
  21. Pensionnyj fond Rossijskoj Federacii. Accessed October 11, 2021. (In Russ.). https://pfr.gov.ru/
  22. Federal’naya sluzhba gosudarstvennoj statistiki. Srednemesyachnaya nominal’naya nachislennaya zarabotnaya plata rabotnikov v celom po ekonomike Rossijskoj Federacii v 1991—2021 gg. Accessed October 11, 2021. (In Russ.). https://rosstat.gov.ru/labor_market_employment_salaries
  23. Federal’naya sluzhba gosudarstvennoj statistiki. Social’no-ekonomicheskoe polozhenie Rossii za yanvar’—aprel’ 2021 goda. Accessed October 11, 2021. (In Russ.). https://rosstat.gov.ru/storage/mediabank/Qurp6hjO/osn-04-2021.pdf
  24. Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess Costs Associated with Patients with Pulmonary Arterial Hypertension in a US Privately Insured Population. Applied Health Economics and Health Policy. 2011;9(5):293-303.  https://doi.org/10.2165/11592430-000000000-00000
  25. Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC. The cost to managed care of managing pulmonary hypertension. Journal of Medical Economics. 2012;15:500-508.  https://doi.org/10.3111/13696998.2012.665109
  26. Dedov II, Kalashnikova MF, Belousov DY, Kolbin AS, Rafalskiy VV, Cheberda AE, et al. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-T2DM). Saharnyj diabet. 2017;20(6):403-419. (In Russ.). https://doi.org/10.14341/DM9278
  27. Kontsevaya AV, Kalinina AM, Koltunov IE, Oganov RG. Socio-economic damage from acute coronary syndrome in the Russian Federation. State Research Center for Preventive Medicine. Racional’naya farmakoterapiya v kardiologii. 2011;7(2):158-166. (In Russ.). https://doi.org/10.20996/1819-6446-2011-7-2-158-166
  28. Kolbin AS, Tatarsky BA, Biserova IN, Zagorodnikova KA, Balykina YE, Proskurin MA, Belousov DY. Socio-economic burden of atrial fibrillation in the Russian Federation. Klinicheskaya farmakologiya i terapiya. 2010;19(4):17-22. (In Russ.).
  29. Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Services Research. 2014;14:676.  https://doi.org/10.1186/s12913-014-0676-0
  30. Burger CD, Ozbay AB, Lazarus HM, Riehle E, Montejano LB, Lenhart G, White RJ. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. The Journal of Managed Care and Specialty Pharmacy. 2018;24(8):834-842.  https://doi.org/10.18553/jmcp.2018.17391

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.